143610-62-2

Usage

Uses

Used in Organic Synthesis:
3-FLUORO-4-METHOXYMETHOXYPHENYLBORONIC ACID is used as a reagent in organic synthesis for the formation of carbon-carbon bonds through Suzuki-Miyaura cross-coupling reactions. Its versatile reactivity allows for the creation of various complex organic molecules, which are essential in the synthesis of pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-FLUORO-4-METHOXYMETHOXYPHENYLBORONIC ACID is used as a key intermediate in the development of new drugs and bioactive compounds. Its unique chemical properties enable the design and synthesis of novel drug candidates with improved therapeutic profiles. 3-FLUORO-4-METHOXYMETHOXYPHENYLBORONIC ACID's potential applications in medicinal chemistry include the development of drugs for various therapeutic areas, such as oncology, neurology, and infectious diseases.
Used in Agrochemistry:
3-FLUORO-4-METHOXYMETHOXYPHENYLBORONIC ACID also finds applications in agrochemistry, where it is used as a building block for the synthesis of agrochemicals, such as pesticides and herbicides. Its reactivity and properties allow for the development of new and more effective agrochemicals with improved selectivity, safety, and environmental compatibility.
Used in Material Science:
In the field of material science, 3-FLUORO-4-METHOXYMETHOXYPHENYLBORONIC ACID is utilized for the synthesis of advanced materials with unique properties. Its versatile reactivity enables the creation of new materials with applications in various industries, such as electronics, energy, and nanotechnology. 3-FLUORO-4-METHOXYMETHOXYPHENYLBORONIC ACID's potential applications in material science include the development of new materials for sensors, catalysts, and functional coatings.

Upstream product

• 2105-94-4 4-bromo-2-fluorophenol 
• 107-30-2 chloromethyl methyl ether 

Relevant academic research and scientific papers

Synthesis, phase-transition behaviors, and birefringence properties of fluorinated diphenyldiacetylene derivatives

We designed fluorinated diphenyldiacetylenebased liquid crystal (LC) molecules that exhibit enantiotropic nematic phases near room temperature. These LC molecules also show high birefringence (Δn ≈ 0.35) similar to their non-fluorinated analogs

CYCLIC COMPOUND HAVING SUBSTITUTED PHENYL GROUP

An object of the present invention is to provide a novel low molecular weight compound exhibiting an osteogenesis-promoting action. This object is achieved by a compound having the general formula (I) or a pharmacologically acceptable salt thereof: wherein each substituent is defined as follows: R1 represents an alkyl group or the like; R2 represents an alkyl group or the like; R3 represents a hydrogen atom or the like; and Z represents -CH= or -N=.

Structure-activity relationships comparing N-(6-methylpyridin-yl)- substituted aryl amides to 2-methyl-6-(substituted-arylethynyl)pyridines or 2-methyl-4-(substituted-arylethynyl)thiazoles as novel metabotropic glutamate receptor subtype 5 antagonists

The metabotropic glutamate receptor subtype 5 (mGluR5) has been implicated in anxiety, depression, pain, mental retardation, and addiction. The potent and selective noncompetitive mGluR5 antagonist 2-methyl-6-(phenylethynyl)pyridine (MPEP, 1) has been a critically important tool used to further elucidate the role of mGluR5 in these CNS disorders. In an effort to provide novel and structurally diverse selective mGluR5 antagonists, we previously described a set of analogues with moderate activity wherein the alkyne bond was replaced with an amide group. In the present report, extended series of both amide and alkyne-based ligands were synthesized. MGluR5 binding and functional data were obtained that identified (1) several novel alkynes with comparable affinities to 1 at mGluR5 (e.g., 10 and 20-23), but (2) most structural variations to the amide template were not well tolerated, although a few potent amides were discovered (e.g., 55 and 56). Several of these novel analogues show drug-like physical properties (e.g., cLogP range = 2-5) that support their use for in vivo investigation into the role of mGluR5 in CNS disorders.

Discovery of orally bioavailable cathepsin S inhibitors for the reversal of neuropathic pain

Cathepsin S inhibitors are well-known to be an attractive target as immunological therapeutic agents. Recently, our gene expression analysis identified that cathepsin S inhibitors could also be effective for neuropathic pain. Herein, we describe the effic

RECEPTOR FUNCTION REGULATING AGENT

An agent for regulating 14273 receptor function, which is useful as a preventing or treating drug for diabetes mellitus, hyperlipidemia or the like, is provided. An agent for regulating 14273 receptor function comprising a compound containing an aromatic ring and a group capable of releasing a cation.

Cyclobutanecarboxylic acid derivatives and liquid crystalline compositions containing them

An optically inactive cyclobutanecarboxylic acid derivative of the general formula STR1 wherein R1 is a hydrogen atom or a straight or branched chain alkyl group having 1-14 carbon atoms, R2 is a straight or branched chain alkyl grou